Skip to main content

Investors

At this page you will find information about Arcomas business and financial position. The information at this page is aimed at shareholders and potential investors.

Årsredovisning 2022

Klicka på knappen nedan för att ladda ner vår årsredovisning för 2022.

Läs årsredovisning

Arcoma förlänger trend av stark tillväxt

Arcomas nytillträdde VD Mattias Leire intervjuas av aktieanalytiker Hjalmar Jernström från Erik Penser Bank. Intervjun berör Mattias bakgrund och Arcomas nyligen publicerade Q1-rapport.

Investor news

Kvartalsrapport Q2 2023 är nu publicerad.

Kvartalsrapport Q2 2023 – Fortsatt tillväxt – Omsättningen ökar med 24% (MAR) https://www.globenewswire.com/news-release/2023/04/27/2655894/0/sv/Kv…
Read more

Senaste analysen av Arcoma – Förlänger trend av stark tillväxt

Arcoma förlänger trenden med ett tredje kvartal av intäktstillväxt som överskrider 30%. Nettoomsättningen i första kvartalet växte 55% y/y, drivet …
Read more

Kvartalsrapport Q1 2023 är nu publicerad.

Positivt momentum – nettoomsättningen ökar med 55% (MAR). https://www.globenewswire.com/news-release/2023/04/27/2655894/0/sv/Kvartalsrapport-Q1-202…
Read more

Årsredovisning 2022 är nu publicerad.

Årsredovisningen går att läsa på vår hemsida samt i denna pressrelease. https://www.globenewswire.com/news-release/2023/04/06/2642272/0/sv/%C3%85rs…
Read more

Intervju med Arcomas VD Sanna Rydberg om kvartalsrapporten för Q2 2022.

Erik Penser Bank har den 18/8 2022 gjort en intervju med Arcomas VD, Sanna Rydberg där hon berättar om kvartalrapporten för andra kvartalet 2022. I…
Read more

Company presentations & interviews

  • 2021-11-16: Arcomas VD Sanna Rydberg intervjuas av aktieanalytiker Hjalmar Jernström på Erik Penser Bank. Se intervjun.

  • 2021-10-07: Sanna Rydberg och Linda Ungsten presenterar Arcoma på Erik Penser Banks temadag om Medicinteknisk mjukvara. Se presentationen.
  • Årsstämma 2020 – Sanna Rydberg, VD Arcoma sammanfattar 2020 och blickar framåt. Se video
  • 2021-05-25: Sanna Rydberg presenterar Arcoma på Erik Penser Banks temadag om Medicinsk Bildteknik & Diagnostik. Se presentationen.
  • 2021-02-22: Arcomas VD Sanna Rydberg intervjuas av aktieanalytiker Hjalmar Jernström på Erik Penser Bank. Länk till video.
  • 2020-11-25: Den 25 november 2020 presenterade Arcomas nya VD, Sanna Rydberg bolaget på Erik Penser Banks bolagsdag samt deltog på en intervju. Länk till Presentation och intervju. 

  • 2020-03-12: Arcoma presenterar på Stockholm Corporate Finance (SCF) tolfte Life Science-seminarium. Videosändning
View more

Interested in investing in Arcoma?

See our company presentation and learn more about Arcoma and our market.

View more presentations

Board of directors

Lars Kvarnhem – Chairman

Lars Kvarnhem, born in 1972, has approximately 20 years of experience in global management and business development of companies and business processes within the MedTech industry.

Previous operational roles have been, among others:

  • CEO and main owner of the MedTech company Anmedic AB, active in anesthesia and intensive Care.
  • President and CEO for Human Care (publ) in healthcare products.
  • Operational Chairman of the MedTech division at Medcap (publ).

Works exclusively as an investor, primarily in the field of Medical Technology. Today Lars holds several board assignments which includes chairman of the board of Arcoma AB (publ), Stille (publ), Absorbets AB, Absorbest Holding AB, Swevet AB, Swevet Holding AB, Reison Medical AB, Part Production AB, Priego AB and Ovon AB, better known as MrCap. Board member Cavis Technologies.

Year of birth 1972
Chairman since 2017
Shares 1 321 925 (2022-12-31) through Priego AB

Other assignments: Chairman of the board of Swevet AB, Reison Medical AB and Ovon AB, better known as MrCap.

Lars is dependent in relation to major shareholders.

Mats Thorén – Board member

Mats Thorén has extensive experience in the medical technology sector, including with Handelsbanken Capital Markets as an account executive for the health sector in Corporate Finance, as an analyst in the biotechnology and medical technology at Enskilda Securities as well as Partner at Catella Healthcare AB. Previous board appointments include inter alia C-Rad AB, Cellartis AB and MIP Technologies AB.

Year of birth 1971
Member/deputy 2012/2010
Shares 668 000 (2022-12-31) directly and through Vixco Capital AB Independent in relation to major shareholders

Other assignments Board member of: Pulsetten AB, Vixco Capital AB, Arcoma Incentive AB and board substitute for Eggelbertus Holding AB.

Mats is independent in relation to major shareholders.

Jan Wahlström – Board member

Jan Wahlström, born in 1967, has extensive experience from leading positions at international companies in medical technology, life science and laboratory instruments. He is the CEO of Mabtech AB since May 2022.

Previous assignments Jan has held are CEO of Elos Medtech, CEO of Biolin Scientific and Chairman of the Board of Insplorion AB.

Year of birth 1967
Member since 2022
Shares 70 000 (2022-12-31)

Other assignments: Jan Wahlström’s other assignments include: Chairman of the Board of Mablax AB, Board member of Alexam AB, Mabtech AB, CEO of Mabtech AB and Mabtech group holding AB.

Jan Wahlström does not hold any shares in the company and is considered to be independent both in relation to the company, its management and in relation to its major shareholders.

Management team

Mattias Leire – VD

Mattias Leire has extensive experience from leading positions, including the last 9 years within Atos Medical.

Mattias has a background as a consultant at McKinsey and Atos Medical, where he held several international roles. These have included CEO roles within subsidiaries, VP & General Manager, VP Business Finance and VP Tracheostomy. Mattias has been involved in several acquisitions and also the sale of Atos Medical from EQT to PAI Partners.

Year of birth 1981
Employeed since 2023
Other assignments None
Own and related party shares 133 500 
Stock options 130 000 (2022/25)
Contact info mattias.leire@arcoma.se

Jesper Lindroos – COO

Jesper Lindroos has extensive experience from the medical technology and manufacturing industry and comes most recently from Getinge Group where he held the position as Chief Project Manager. He has a Master of Science in Mechanical Engineering from Lund University and joined Arcoma during 2020.

Year of birth 1984
Employed since 2020
Other assignments None
Own and related party shares None
Contact info jesper.lindroos@arcoma.se

Johan Dahlberg – CFO

Johan Dahlberg has a master’s degree from Lund University and experience in most roles in finance, such as Business Controller, Accounting Manager and Finance Manager.

Most recently, he came from a business-related role at BIMobject, where he mainly worked with business follow-up. Prior to BIMobject, Johan worked for seven years at Qlik, a leading company in Business Intelligence, including the role of Finance Manager for Qlik’s Nordic sales companies.

Year of birth 1984
Employeed since 2022
Other assignments None
Own and related party shares 0
Contact info johan.dahlberg@arcoma.se

Johan Henningsson – R&D Manager

Johan Henningsson has a bachelor in mechanical engineering at Linné University. Johan has a background as a mechanical engineer at Arcoma.

Year of birth 1971
Employed since 1994, in current position since 2014.
Other assignments None
Own and related party shares 7254
Contact info johan.henningsson@arcoma.se

Linda Ungsten – Product Manager

Linda holds a Master of Science in Engineering from Linköping University of Technology and experience as product manager at Bombardier Transportation and from employment within Radiological Physics at Sahlgrenska University Hospital.

Year of birth 1974
Employed since 2008, in her current position since 2011
Other assignments None
Own and related party shares None
Contact info linda.ungsten@arcoma.se

Henrik Blomdahl – Quality Manager

Henrik Blomdahl has over 20 years of experience in the medical technology industry. Most recently, Henrik comes from Invacare Rea AB, where he had the role of QA/RA Manager Nordics.

Prior to that he worked as a quality technician at Getinge Disinfection in Växjö, focusing on supplier quality, project management and internal and external audits.

Employed since 2021
Other assignments None
Own and related party shares None
Contact info henrik.blomdahl@arcoma.se

Tarik Cengiz – Global Sales Director

Tarik Cengiz holds a Master’s degree in Radiography from Karolinska Institutet and has extensive clinical and commercial experience in Radiology. 

He has held various commercial roles at international medical device companies, including GE Healthcare and Mallinckrodt Pharmaceuticals.”

Employed since 2021
Other assignments None
Own and related party shares: 1 150
Contact info tarik.cengiz@arcoma.se

Share information

According to Articles of Association of Arcoma AB:

  • The share capital shall not be less than 12 000 000 Kronor and no more then 48 000 000 Kronor.
  • The number of shares shall not be less than 6 000 000 shares and no more then 24 000 000 shares.
  • Registered share capital is 26 371 120 kronor.
  • The shares is issued under the Companies Act and is denominated in Swedish kronor.
  • There is only one type of share. All shares carry equal rights to the Company’s assets and results, and are entitled to one vote at the Annual General Meeting. One share equals one vote.
  • Company’s share register is kept by Euroclear Sweden AB (former VPC AB), Box 7822, 103 97 Stockholm. Shareholders of the Company will receive no physical share. All transactions with the Company’s shares are done electronically through authorized banks and broker- dealers. Newly issued shares will be registered in person in electronic format.
  • Issuer and the account operator is Erik Penser Bank, Apelbergsgatan 27, Box 7405, 103 91 Stockholm
  • The shares ISIN-Code is SE0006219176
  • The LEI code is 549300C0DH9EESDQUA52

Shareholders

Register Date: 2023-06-30

Main Share
Holders

  

Percentage of
issued shares

Linc AB

  

24,99%

Sunstone Life Science Ventures Fund II K/S

  

19,65%

Priego AB

  

10,03%

Avanza Pension

   5,52%

Mats Thorén via bolag

   5,07%